Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalteparin sodium for the prevention of venous thromboembolism in advanced pancreatic cancer patients undergoing chemotherapy

Trial Profile

Dalteparin sodium for the prevention of venous thromboembolism in advanced pancreatic cancer patients undergoing chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2013 Results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2013 New trial record
    • 09 Dec 2013 Primary endpoint 'Disease-occurrence-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top